Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies.
Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. SALES OF ANTI-EGF-R ANTIBODIES
2. ORIGINATOR ANTI-EGF-R ANTIBODIES
Erbitux Approved Indications & Pipeline
Vectibix Approved Indications & Pipeline
Nimotuzumab Approved Indications & Pipeline
Portrazza Approved Indications & Pipeline
3. BIOSUPERIOR ANTI-EGF-R ANTIBODIES
3RD GENERATION ANTI-EGF-R ANTIBODIES
Bispecific Anti-EGF-R Antibodies
Anti-EGF-R Antibody Drug Conjugates
4. BIOSIMILAR ANTI-EGF-R ANTIBODIES
Erbitux Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
5. CORPORATE ANTI-EGF-R BIOSIMILAR & BIOSUPERIOR ANTIBODY PIPELINES
2. ORIGINATOR ANTI-EGF-R ANTIBODIES
Erbitux Approved Indications & Pipeline
Vectibix Approved Indications & Pipeline
Nimotuzumab Approved Indications & Pipeline
Portrazza Approved Indications & Pipeline
3. BIOSUPERIOR ANTI-EGF-R ANTIBODIES
3RD GENERATION ANTI-EGF-R ANTIBODIES
Bispecific Anti-EGF-R Antibodies
Anti-EGF-R Antibody Drug Conjugates
4. BIOSIMILAR ANTI-EGF-R ANTIBODIES
Erbitux Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
5. CORPORATE ANTI-EGF-R BIOSIMILAR & BIOSUPERIOR ANTIBODY PIPELINES
